Background Ramucirumab is a human IgG1 monoclonal antibody that targets the
extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with …

Objectives Ramucirumab plus docetaxel prolongs survival in patients with non-small cell
lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II …

BACKGROUND Vascular endothelial growth factor (VEGF)–mediated angiogenesis plays
an important role in non–small cell lung cancer (NSCLC). Ramucirumab is a human …

Background It is unclear whether the chemotherapy response improves after exposure to
immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system …

Background Outcomes are poor for patients with previously treated, advanced or metastatic
non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody …

Introduction The efficacy and safety of atezolizumab versus the efficacy and safety of
docetaxel as second-or third-line treatment in patients with advanced NSCLC in the primary …

Background Despite immunotherapy advancements for patients with advanced or metastatic
non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an …

Background/Aim: For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and
ramucirumab (DOC+ RAM) combination therapy may be more effective compared to patients …

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell
lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular …

Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1)
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and …